Trial data is being withheld for ensuring profits of drug companies by medicine regulators and this has sidelined the safety of patients.

A team of Danish researchers have concluded this and they feel that full trial reports should be accessed by the scientific community in both published and unpublished forms.

As this will enable people to weigh the benefits and harms that a treatment can do.

Reports state that thousands of trials are conducted on drugs but all of them are reported in a selective way and due to this, doctors are not able to seek the best possible course of treatments for their patients, according to researchers.

Due to most of the trial results remaining unpublished, and due to this the actual picture of results are not expressed. This is doing nothing but protecting pharma companies.

Various negative consequences that are disastrous can take shape according to Professor Peter Gotzsche and Dr Anders Jorgensen from the Nordic Cochrane Centre in Denmark due to selective reporting.

Giving example of unreported trials, obesity drug orlistat was given and it took three years to get access to the full trial report.

Gotzsche and Jorgensen said, "The information was important for patients because anti-obesity pills are controversial. People have died from cardiac and pulmonary complications or have experienced psychiatric disturbances."